Luminespib (AUY922) is another drug of this group which demonstrated efficacy and disease regression as a monotherapy in previously treated NSCLC with EGFR gene mutations and ALK rearrangement, and had no particular impact on KRAS-mutant tumors (NCT01124864) [69]. This evidence concerns the gene ALK and non-small cell lung carcinoma.